Clinical Trials

15 enrolled

Carcinoma, Renal Cell

NCT05401786 2026-03-12

RAD-IO

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

36 enrolled

Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT05665348 2026-03-09

TRIPLET

Phase 2/3 Completed

229 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

196 enrolled

Prostatic Neoplasms

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT03026140 2026-03-05

NICHE

353 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms

NCT03223155 2026-03-04

COSINR

78 enrolled

Small Cell Lung Carcinoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Phase 1 Not yet recruiting

Melanoma

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

18 enrolled

Sarcoma

NCT07436390 2026-03-02

MAK

Phase NA Completed

132 enrolled

Melanoma, Skin Neoplasms

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04969887 2026-02-27

MOST-CIRCUIT

240 enrolled

EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

33 enrolled

Phase 1 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07401875 2026-02-27

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

35 enrolled

Kidney Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

17 enrolled 8 charts

Phase 1 Not yet recruiting

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07188896 2026-02-23

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Carcinoma, Renal Cell

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

100 enrolled

Melanoma, Skin Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

Melanoma

NCT03520491 2026-02-17

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

52 enrolled

MyeloidOther hematologic neoplasm

Urinary Bladder Neoplasms

NCT03600155 2026-02-17

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Phase NA Recruiting

28 enrolled

Pancreatic Neoplasms

NCT05928806 2026-02-11

ARCITECT

Phase 2 Suspended

120 enrolled

Advanced Renal Cell Carcinoma

NCT07230613 2026-02-11

NEOREM-NEO-1

50 enrolled

Phase 2 Not yet recruiting

Melanoma

NCT07403877 2026-02-11

TORCH-OPTIMA

114 enrolled

Phase 1 Active not recruiting

Turcot syndrome, Colorectal Neoplasms

NCT00586391 2026-02-06

CRETI-NH

14 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03203473 2026-02-06

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

85 enrolled 17 charts

Kidney Neoplasms

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

30 enrolled 15 charts

Breast

Breast Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Phase 1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT02950766 2026-02-03

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

19 enrolled

Kidney Neoplasms

NCT03340129 2026-02-02

ABC-X

218 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

29 enrolled

Melanoma, Skin Neoplasms

NCT06365619 2026-01-29

NeoRelapse

25 enrolled

Melanoma

NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

30 enrolled 14 charts

Head & Neck

Head and Neck Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

39 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 1/2 Active not recruiting

40 enrolled 14 charts

CNS

Meningioma

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1 Recruiting

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

214 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

100 enrolled

EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT04413123 2026-01-21

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

60 enrolled

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07355205 2026-01-21

FLINN

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03285321 2026-01-20

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

39 enrolled 18 charts